Nobody at the Dermatology Clinic Is Going to Judge Your Routine

The rehearsed defence nobody asks you to give

People arrive at an acne appointment with a speech prepared. Some have rehearsed an apology for a bathroom shelf of half-used products; others have rehearsed a defence of having tried nothing at all. Neither speech gets requested, because the clinician is not running a moral audit. They are running a triage: how bad, what type, what has genuinely been tried, and what is the next rung.

The fear that keeps people out of the room is usually one of three: that the answer will be isotretinoin whether they like it or not, that the visit will not be worth what it costs, or that they will be told to wash their face better. The last one is the easiest to dispose of. The current guideline's recommendations are pharmacological; there is no line in it about scrubbing harder.

What follows is the actual sequence — history, examination and grading, plan, follow-up — and what each part is really looking for. Our derm-visit-prep tool builds the notes for the first part so you arrive with answers rather than approximations.

The history: 'I tried a retinoid' is not an answer

The single most valuable thing you bring is a precise treatment history, because it decides whether a step counts as failed. A topical retinoid needs roughly twelve weeks of consistent use before its effect can be read. Someone who applied ↗Proactiv Adapalene Gel 0.1% nightly for three weeks, got flaky and stopped, has not failed a retinoid — they have had an introduction problem, and the fix is a slower ramp rather than a new prescription.

So the questions are granular. Which product, at what strength. How many nights a week, honestly. For how many weeks. What made you stop — irritation, cost, boredom, or genuine lack of effect. Whether you used it alone or alongside a wash like ↗PanOxyl 4% Benzoyl Peroxide Creamy Wash. Whether anything worked and then stopped working.

The rest of the history covers ground that is less obviously about skin: medications that provoke acneiform eruptions, any previous course of isotretinoin and its outcome, menstrual regularity and pregnancy plans for anyone who might be prescribed a hormonal agent or a retinoid, and family history of severe acne or scarring. None of it is judgement. All of it narrows the list.

If you cannot reconstruct the timeline from memory — most people cannot — photographs solve it. Our photo-tracker exists for exactly this: a dated series showing what your skin looked like at the start of a course and twelve weeks in is worth more than any recollection, and it settles the 'is this actually better' argument that otherwise runs on vibes. The answers people most often need before booking are collected in ↗the acne question library.

The examination: they are grading, and looking past the spots

The examination takes a couple of minutes and is doing more than it appears. The clinician is separating lesion types, because the mix drives the drug: comedonal acne points one way, inflammatory papules and pustules another, nodules and cysts another again. They are noting distribution — jawline and lower face has different implications from a diffuse T-zone pattern. And they are looking at what the acne has left behind.

That last part is the one patients underestimate. Post-inflammatory hyperpigmentation and early atrophic scarring are not cosmetic footnotes; they change the urgency of the plan. The guideline treats scarring as an explicit trigger for escalating to systemic therapy, which means visible scarring can move you up the ladder faster than lesion count alone would. ↗The scarring pathway covers what happens after, but the leverage is here, at the point where preventing the next scar is still possible.

They will also ask to see your back and chest, because truncal involvement is common, frequently unmentioned, and changes what is practical to prescribe. Wear something that makes this easy. If you want a sense of where you sit before you go, our acne-severity tool applies the same lesion-type-and-count logic clinicians use, which at minimum gives you shared vocabulary in the room.

The prescription list is longer than you think

The 2024 American Academy of Dermatology acne guideline contains 18 evidence-based recommendations and 5 good practice statements. Strong recommendations go to benzoyl peroxide, topical retinoids, topical antibiotics and oral doxycycline. Conditional recommendations cover topical clascoterone, salicylic acid and azelaic acid, plus oral minocycline, sarecycline, combined oral contraceptive pills and spironolactone. Isotretinoin is strongly recommended, but for a defined situation: acne that is severe, that is scarring, that carries psychosocial burden, or that has failed standard oral or topical therapy.

Read that list again and notice how much of it is topical, and how much of the combination logic you can already see in over-the-counter form. One of the good practice statements is to combine topicals with multiple mechanisms of action rather than stacking more of the same — the principle behind a fixed-dose product like ↗Differin Epiduo Acne Gel, which pairs a retinoid with ↗benzoyl peroxide in one step, and behind a dual-action treatment such as ↗La Roche-Posay Effaclar Duo.

Two further good practice statements shape what you should expect to be told. Systemic antibiotic use should be limited, and when a systemic antibiotic is used it should be combined with topical therapy rather than run alone. If you leave with doxycycline and nothing else, that is worth a question. Clascoterone is the genuinely new entry — a topical androgen receptor inhibitor, the first fresh mechanism in acne in a long time, and prescription-only.

A prescription does not replace the routine around it, either. A cleanser that does not strip, such as ↗CeraVe Acne Foaming Cream Cleanser, and a moisturiser you will actually keep using are what make an irritating active survivable. Our ↗retinoid ranking is the shortlist for the over-the-counter half of that.

The hormonal question, and what actually gets tested

Adult women with jawline acne often arrive expecting a blood test, and are surprised when one is not ordered. Hormonal testing is reserved for people showing signs that suggest an underlying endocrine cause — irregular or absent periods, hirsutism, rapid onset with virilising features — rather than run routinely, because acne without those signs usually has normal androgen levels.

Which is the point that gets missed: normal levels do not disqualify you from hormonal treatment. The largest randomised trial of spironolactone for acne enrolled 410 adult women in England and Wales on the criterion that their facial acne was judged to warrant oral antibiotics, not that they had demonstrated hormonal abnormality. Participants took 50 mg daily to week six, then 100 mg to week 24, against matched placebo, and were allowed to continue topical treatment.

The results are worth knowing in both directions. At twelve weeks, the difference in acne-specific quality of life favoured spironolactone by a small margin whose confidence interval nearly touched zero. By twenty-four weeks the gap was substantially wider. That is a drug that works and works slowly — a legitimate antibiotic-sparing option for adult women, and a poor choice for anyone who will judge it at week eight and quit.

If isotretinoin does come up

It might. It is the most effective drug in the category and the guideline is unambiguous about where it belongs. But it arrives with a conversation, not a prescription pad, and the two things people fear most about it are worth putting in proportion.

On monitoring: a meta-analysis pooling 26 studies and 1,574 patients found that mean triglyceride, cholesterol, LDL, HDL, AST, ALT, alkaline phosphatase and white cell values measured during isotretinoin therapy all sat within standard normal reference ranges. Meaningful abnormalities happen and are worth catching, but the pattern in the aggregate data does not support the monthly-bloods-forever model many people still picture.

On pregnancy: this part is not negotiable and is not clinician discretion. Isotretinoin is a potent teratogen, and in the United States it is dispensed only through a mandatory risk management programme involving registration, pregnancy testing and monthly authorisation for anyone who can become pregnant. If that framework is not workable for you right now, say so early — it changes which branch of the plan you are on, and there are other branches.

Follow-up, and what counts as failure

You will usually be booked back at around twelve weeks, and that number is not arbitrary — it is roughly how long a topical or oral course needs before the effect can be read. Between those two appointments, the job is adherence, not evaluation. Skin assessed in the mirror at week four, under bathroom lighting, in a bad mood, is not data.

Failure has a definition too, and it is narrower than the everyday use of the word. A course has failed when it has been taken as prescribed, for an adequate duration, and the lesion count has not moved. A course you abandoned in week three because it stung has not failed; it has been interrupted, and the fix is usually a gentler vehicle, a lower frequency, or buffering with moisturiser rather than an entirely different drug. Being precise about that distinction at the follow-up is what stops you cycling through the whole list while never completing any of it.

The honest summary is that the appointment most people are avoiding is a fifteen-minute conversation with a longer menu than they expect and less drama than they fear. If you want to see the full escalation logic before you book — what typically comes first, what comes next, and what triggers a move upward — ↗the acne therapy pathway lays it out end to end. The worst outcome is not being offered a drug you did not want. It is spending two more years at a rung you had already outgrown.